Harpoon Therapeutics Revenue and Competitors

Location

#4617

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Harpoon Therapeutics's estimated annual revenue is currently $26.8M per year.(i)
  • Harpoon Therapeutics received $70.0M in venture funding in November 2018.
  • Harpoon Therapeutics's estimated revenue per employee is $425,714
  • Harpoon Therapeutics's total funding is $130M.
  • Harpoon Therapeutics's current valuation is $191.6M. (January 2022)

Employee Data

  • Harpoon Therapeutics has 63 Employees.(i)
  • Harpoon Therapeutics grew their employee count by 13% last year.

Harpoon Therapeutics's People

NameTitleEmail/Phone
1
Sr. Executive Assistant to the CMOReveal Email/Phone
2
Sr VP, Human ResourcesReveal Email/Phone
3
VP, Information TechnologyReveal Email/Phone
4
SVP, Business DevelopmentReveal Email/Phone
5
ControllerReveal Email/Phone
6
VP Protein ScienceReveal Email/Phone
7
SVP, Translational MedicineReveal Email/Phone
8
SVP, Product Development, Technical and Manufacturing OperationsReveal Email/Phone
9
VP ResearchReveal Email/Phone
10
Director, TM OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Harpoon Therapeutics?

Harpoon Therapeutics is a clinical stage biotechnology company co-founded by Patrick Bauerle, a pioneer in T-cell engagement, and Luke Evnin (MPM Capital) in 2015 to develop and commercialize a novel class of T cell recruiting antibodies engage a patient's own immune cells to fight cancer and other diseases. The world-class team of protein engineers and immunologists at Harpoon have built upon the successful development of the bispecific (BiTE or bispecific T cell engager) antibody Blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. Harpoon's tri-specific T-cell redirection platform -- TriTAC -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, CAR-T and other T-cell engaging approaches by improving activity against solid tumors convenience of administration treatment of more tumor types and other immunologic diseases. Harpoon has discovered proprietary drug candidates and has an expansive research portfolio leveraging the TriTAC platform. Harpoon plans to file its first 2 INDs and initiate its first clinical study in 2018. Harpoon Therapeutics recently completed a Series B financing round with investors: MPM Capital, New Leaf Venture Partners, Arix Biosciences, and Taiho Ventures.

keywords:N/A

$130M

Total Funding

63

Number of Employees

$26.8M

Revenue (est)

13%

Employee Growth %

$191.6M

Valuation

N/A

Accelerator

Harpoon Therapeutics News

2022-04-13 - Harpoon Therapeutics Presents Preclinical Data for TriTAC ...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy...

2022-04-13 - Harpoon Therapeutics Presents Preclinical Data for TriTAC ...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing...

2022-04-06 - Harpoon Therapeutics Shares Drop 14% After Chief Medical Officer Natalie Sacks Steps Down

By Chris Wack. Harpoon Therapeutics Inc. shares were down 14% after the company said Chief Medical Officer Natalie Sacks will be leaving the...

2019-09-08 - Analysts Expect Harpoon Therapeutics (HARP) Stock to Rise 74%; Rated Strong Buy

Harpoon Therapeutics Inc (HARP) stock has fallen -2.14% since Thursday, February 7, 2019 when Harpoon Therapeutics Inc began trading.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.2M63N/AN/A
#2
$4.9M63-53%$195.7M
#3
$12M65-10%N/A
#4
N/A65141%N/A
#5
$8.3M66-3%$80.9M

Harpoon Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-05-26$45.0MBArix BioscienceArticle
2018-11-12$70.0MCOrbiMedArticle